Skip to Main Content

Paper Details

Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma.
Cancer Immunol Res
4
2023
Atezolizumab, Bevacizumab, CD4, CD8, CD8+, CD8+PD-L1+ T cells, LAG-3, Metastatic RCC, PD, PD-1, PD-L1, PD-L1+, PD-L1+ T cells, Patients, RCC, Renal cell carcinoma, Sarcomatoid Renal Cell Carcinoma, T cells, TIM-3, VEGF-A, atezolizumab, bevacizumab, circulating, kidney cancer, patients, peripheral immune cell populations, tumor, vascular endothelial growth factor A
Author NameAffiliation
Eliezer M Van AllenLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School
Toni K ChoueiriLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School
  • 1 - 2

Datasets

Release 1.2